Teachers Retirement System of The State of Kentucky held its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,700 shares of the biotechnology company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Momenta Pharmaceuticals were worth $210,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in Momenta Pharmaceuticals during the first quarter valued at $158,000. BNP Paribas Arbitrage SA raised its position in Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 1,570 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Momenta Pharmaceuticals by 3.0% in the first quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 411 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its position in Momenta Pharmaceuticals by 2.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 14,600 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 310 shares in the last quarter. Finally, Mason Street Advisors LLC raised its position in Momenta Pharmaceuticals by 8.3% in the first quarter. Mason Street Advisors LLC now owns 15,122 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 1,154 shares in the last quarter. Hedge funds and other institutional investors own 86.89% of the company’s stock.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded down 1.85% during midday trading on Friday, reaching $15.90. 746,780 shares of the company traded hands. Momenta Pharmaceuticals, Inc. has a 12-month low of $10.66 and a 12-month high of $19.90. The company’s market cap is $1.18 billion. The company has a 50-day moving average price of $16.80 and a 200-day moving average price of $15.69.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same period last year, the company posted ($0.31) earnings per share. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals, Inc. will post ($1.20) earnings per share for the current fiscal year.

WARNING: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://theolympiareport.com/2017/08/12/teachers-retirement-system-of-the-state-of-kentucky-has-210000-position-in-momenta-pharmaceuticals-inc-nasdaqmnta.html.

Several equities analysts have recently commented on MNTA shares. Barclays PLC lowered shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $20.00 to $17.00 in a research report on Monday, May 22nd. Cowen and Company restated a “hold” rating and set a $15.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Maxim Group set a $6.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a research report on Wednesday, May 3rd. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $16.63.

In related news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $15.83, for a total value of $65,156.28. Following the transaction, the president now owns 281,919 shares in the company, valued at $4,462,777.77. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 5,996 shares of company stock worth $94,323. 4.40% of the stock is owned by company insiders.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.